A5054008156- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Viral-associated cancers and disorders
- Chronic Myeloid Leukemia Treatments
- CNS Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Advanced Breast Cancer Therapies
- Glycosylation and Glycoproteins Research
- Immune Cell Function and Interaction
- Genetic factors in colorectal cancer
- Hematopoietic Stem Cell Transplantation
- Cutaneous lymphoproliferative disorders research
- Cancer Immunotherapy and Biomarkers
- Phagocytosis and Immune Regulation
- Epigenetics and DNA Methylation
- Glioma Diagnosis and Treatment
- Galectins and Cancer Biology
- Sarcoma Diagnosis and Treatment
- RNA modifications and cancer
Universitat Autònoma de Barcelona
2016-2025
Vall d'Hebron Hospital Universitari
2016-2025
Vall d'Hebron Institute of Oncology
2017-2024
Hebron University
2015-2024
Vall d'Hebron Institut de Recerca
2017-2024
University of Siena
2023
Spanish Clinical Research Network
2021
Cancer Genetics (United States)
2001-2019
Columbia University
2019
München Klinik
2015
The mutational status of immunoglobulin heavy-chain variable-region (IgVH ) genes in the leukemic cells chronic lymphocytic leukemia (CLL) is an important prognostic factor disease. We investigated whether expression ZAP-70 by CLL correlated with IgVH status, disease progression, and survival.
Mantle cell lymphoma (MCL) is typically a very aggressive disease with poor outcomes, but some cases display an indolent behavior that might not necessitate treatment at diagnosis. To define molecular criteria permit recognition of such cases, we compared the clinicopathologic features, gene expression, and genomic profile patients who had or conventional (iMCL cMCL). Patients iMCL displayed nonnodal leukemic predominantly hypermutated IGVH noncomplex karyotypes. cMCL shared common...
Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage eliminate malignant B being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).This first-in-human trial (ClinicalTrials.gov identifier: NCT02500407) evaluated the safety tolerability efficacy of mosunetuzumab in patients with R/R B-NHL established recommended phase II dose. Data from dose escalation are presented. Single-agent was administered intravenously 3-week...
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor outcome. Given increasing number new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce time necessary to assess their efficacy. this European Research Initiative on (ERIC) project we have identified and validated flow-cytometric approach reliably quantitate cells 0.0010% (10−5). The assay comprises core panel six markers (i.e. CD19,...
Abstract Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into very aggressive large B cell lymphoma conferring dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses functional experiments, 19 cases CLL developing RT. Studying 54 longitudinal samples covering up to years disease course, we uncovered minute subclones...
As part of a phase 1 or 2 study, this single-arm expansion cohort established the efficacy and safety mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (received ≥2 previous lines therapy). Intravenous was administered cycle (C) step-up dosing for cytokine release syndrome (CRS) mitigation: C1 day (D) 1: mg; C1D8 C1D15 C2D1: 60 C3 + D1: 30 mg. Hospitalization not mandatory. Patients complete response (CR) completed treatment after C8;...
JCO
<h3>Background</h3> Twenty percent of patients with multiple myeloma (MM) have renal failure. <h3>Objective</h3> To analyze the presenting features, response to therapy, and factors associated function recovery survival in 94 MM <h3>Patients Methods</h3> Medical records from our institution failure diagnosed between January 1969 December 1994 were reviewed. The statistical methods consisted Kaplan-Meier curves, log-rank test, logistic regression analysis, Cox proportional hazards model for...
The goal of this study was to analyze the presenting features, natural history, and prognostic factors in 59 patients with well characterized mantle cell lymphoma (MCL).Cases were classified as nodular or diffuse typical blastic variants. Age, performance status (PS), histologic variants, mitotic index (MI), hematologic parameters, tumor extension data, International Prognostic Index (IPI) recorded evaluated for prognosis.The median age 63 years (range, 39-83 years), male female ratio 3:1....
Purpose To study the main clinicobiologic features, response, and outcome of patients with diffuse large B-cell lymphoma (DLBCL) according to primary site, lymph node, or different extranodal organs disease. Patients Methods We included 382 consecutively diagnosed DLBCL in a single institution during 13-year period. Morphology, immunophenotyping, proliferation index, differentiation profile, bcl-2/JH rearrangement, clinical characteristics were analyzed site lymphoma. Results Sites disease...
PURPOSE Variables used to build up the International Index for aggressive lymphomas (age, performance status, stage, extranodal involvement, and lactic dehydrogenase [LDH]) are also important in low-grade lymphoma. To assess prognostic value of this index lymphoma, we have applied it a series 125 patients. PATIENTS AND METHODS One hundred twenty-five patients with lymphoma who were diagnosed at single institution over 20-year period treated standard chemotherapy studied. End points study...